LinkedIn Profile

Access Acarix historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:acarix 735472 Dec 3rd, 2020 12:00AM Acarix 673 14.00 Open Medical Device Dec 3rd, 2020 08:36AM Dec 3rd, 2020 08:36AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Dec 2nd, 2020 12:00AM Acarix 672 14.00 Open Medical Device Dec 2nd, 2020 10:32AM Dec 2nd, 2020 10:32AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Dec 1st, 2020 12:00AM Acarix 671 14.00 Open Medical Device Dec 1st, 2020 09:36AM Dec 1st, 2020 09:36AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Nov 30th, 2020 12:00AM Acarix 670 14.00 Open Medical Device Nov 30th, 2020 09:55AM Nov 30th, 2020 09:55AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Nov 29th, 2020 12:00AM Acarix 668 14.00 Open Medical Device Nov 29th, 2020 04:41PM Nov 29th, 2020 04:41PM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Nov 28th, 2020 12:00AM Acarix 668 14.00 Open Medical Device Nov 28th, 2020 12:33PM Nov 28th, 2020 12:33PM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Nov 27th, 2020 12:00AM Acarix 664 14.00 Open Medical Device Nov 27th, 2020 08:53AM Nov 27th, 2020 08:53AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Nov 26th, 2020 12:00AM Acarix 660 14.00 Open Medical Device Nov 26th, 2020 09:54AM Nov 26th, 2020 09:54AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Nov 25th, 2020 12:00AM Acarix 656 14.00 Open Medical Device Nov 25th, 2020 11:52AM Nov 25th, 2020 11:52AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology
private:acarix 735472 Nov 24th, 2020 12:00AM Acarix 655 14.00 Open Medical Device Nov 24th, 2020 08:41AM Nov 24th, 2020 08:41AM Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway. Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient. Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark. Open Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease Open Jungmansgatan 12 Malmö Skane County SE 211 11 Acarix Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.